Home Current Archive Editorial Team
About us
Aims and scope About Author Guidelines
News Contact
×
Home Current Archive Editorial board

Aims and scope About Author Guidelines
News Contact
Review paper
Published: 01.12.2015. Biochemistry
<< Prev | Next >>
PDF
https://doi.org/10.17392/824-16

Predicting recurrence of non-muscle-invasive bladder cancer after transurethral resection

By
Haris Đug ,
Haris Đug
Contact Haris Đug

Department of Urology, Clinic of Surgery, University Clinical Centre of Tuzla, Tuzla, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Samed Jagodić ,
Samed Jagodić

Department of Urology, Clinic of Surgery, University Clinical Centre of Tuzla, Tuzla, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Jasmina Ahmetović-Ðug ,
Jasmina Ahmetović-Ðug

Clinic of Anesthesiology and Reanimation, University Clinical Centre of Tuzla, Tuzla, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Zijad Selimović ,
Zijad Selimović

Department of Urology, Clinic of Surgery, University Clinical Centre of Tuzla, Tuzla, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Alemdar Sulejmanović
Alemdar Sulejmanović

Department of Urology, Clinic of Surgery, University Clinical Centre of Tuzla, Tuzla, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar

Abstract

Aim
 To determine clinical prognostic factors and their impact on the risk of recurrence of newly discovered non-muscle-invasive
bladder cancer.
Methods
 The study included 120 patients of both sexes aged 45-80 years with newly discovered non-muscle-invasive bladder cancer. All the patients were treated surgically by transurethral electro resection (TUER). The outcome of patients with and without recurrence was followed at intervals of three months after surgery, the total of two years. For monitoring the probability of early recurrence the criteria of the European Organization for Research and Treatment of Cancer (EORTC) were used.
Results
 The average age of the patients was 65.9 years, 79 (79.2%) males and 21 (20.8%) females. The total of 67 (55.8%) patients had a recurrence during the period of monitoring. The average time to the first and fourth recurrence was 15.4 and 23.9 months, respectively. Numbers of tumors and a degree of invasion had a significant prognostic impact on the risk of recurrence. The EORTC score was a highly significant predictor of recurrence (OR=1.237; p<0.001).
Conclusion
Based on available clinical and pathological prognostic factors and by stratification of patients into three disease risk
groups it is possible to predict the possibility of disease. Individual approach and recommendations for the treatment using EORTC risk tables should improve the quality of treatment.

Keywords:

immunotherapy,
probability,
treatment

References

1.
Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D, et al. Cancer incidence and mortality worldwide: IARC CancerBase. International Agency for Research on Cancer; 2008.
2.
Bosseti C, Bertuccio P, Chatenoud L, Negri E, Vecchia L, Levi C, et al. Tends in mortality from urologic cancers in Europe. EurUrol. 1970. p. 1–15.
3.
Farlay J, Randi G, Bosetti C, Levi F, Negri E, Boyle P, et al. Declining mortality from bladder cancer in Europe. BJU Int. 2008. p. 11–9.
4.
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. EurUrol. 2011. p. 997–1008.
5.
Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. EurUrol. 2013. p. 234–41.
6.
Abern M, Dude A, Tsivian M, Coogan C. The characteristic of bladder after radiotherapy for prostate cancer. UrolOncol. 2013. p. 1628–34.
7.
Sylvester R, Van Der Meijden A, Oosterlinck W, Witjes J, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage TaT1 urinary bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. EurUrol. 2006. p. 466–75.
8.
Millán-Rodriguez F, Chéchile-Toniolo G, Bayarri S, Palou J, Algaba J, F, et al. Primary superficial urinary bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000. p. 680–4.
9.
Brausi M, Witjes J, Lamm D, Persad R, Palou J, Colombel M, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer group. J Urol. 2011. p. 2158–67.
10.
Sangar V, Ragaven N, Matanheleia S, Wtson M, Blades R. The economic consequences of prostate and bladder cancer in UK. BJU Int. 2005. p. 59–63.
11.
May M, Brookman-Amissah S, Roigas J, Hartmann A, Storkel S, Kristiansen G, et al. Prognostic accuracy of individual uropathologists in Non-invasive urinary bladder carcinoma: a multicenter study comparing the 1973 and 2004 World Health Organisati-onClassifications. EurUrol. 2010. p. 850–8.
12.
Epstein J, Amin M, Reuter V, Mostofi F. The World Health Organization/ International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J SurgPathol. 1998. p. 1435–48.
13.
Seo K, Kim B, Park C, Kim C, Ii, Chang H. The efficacy of the EORTC Scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus Calmette-Guerin instillation. Korean J Urol. 2010. p. 165–70.
14.
Vedder M, Márquez M, De Bekker-Grob E, Calle M, Dyrskjøt L, Kogevinas M, et al. Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumors. Plos One. 2014. p. 96849.
15.
Malmström P, Sylvester R, Crawford D, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesicalmitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. EurUrol. 2009. p. 247–56.
16.
Bobinski J, Lipinski M. The value of EORTC risk tables in evaluating the results of patient treated for non-muscle-invasive bladder cancer with TUR. C E J Urol. 2009. p. 237–42.
17.
Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Ojea A, et al. Club Urológico Español de Tratamiento Oncológico. The EORTC tables overestimate the risk of recurrence and progression in patient with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Guerin. External validation of the EORTC risk tables. EurUrol. 2011. p. 423–30.
18.
Predviđanje rizika recidiva mišićnih neinvazivnih karcinoma mokraćnog mjehura nakon transuretralne resekcije Haris Ðug 1 , Samed Jagodić 1. Alemdar Sulejmanović 1.
19.
Klinika za hirurgiju, 2 Klinika za anesteziologiju i reanimatologiju; Univerzitetski klinički centar Tuzla; Tuzla, Bosna i Hercegovina SAŽETAK Cilj Utvrditi kliničke prognostičke faktore i odrediti njihov utjecaj na rizik od recidiva novootkrivenih mišičnih neinvazivnih karcinoma mokraćnog mjehura.
20.
Metode Studijom je obuhvaćeno 120 pacijenata oba spola, starosti od 45 do 80 godina s novootkrivenim mišićnim neinvazivnim karcinomom mokraćnog mjehura. Svi ispitanici su tretirani operativnim zahvatom transuretralne elektroresekcije (TUER).
21.
Rezultati Prosječna dob ispitanika iznosila je 65,9 godina.
22.
Zaključak Na osnovu dostupnih kliničkih i patoloških faktora, te stratifikacijom pacijenata na tri grupe rizika od oboljenja, moguće je predvidjeti izglede recidiva oboljenja. Individualni pristup i preporuke u liječenju, koristeći EORTC-ove tablice rizika, trebalo bi da poboljšaju kvalitet liječenja.

Citation

Copyright

Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

 

Article metrics

Google scholar: See link

{{ submission.title }}
Issue image
Vol 13, Issue 1, 2016
Does odor and taste identification change during hyperemesis gravidarum? Predicting recurrence of non-muscle-invasive bladder cancer after transurethral resection Mean platelet volume predicts the glycemic control deterioration in diabetes mellitus type 2 patients Proenkefalin A and protachykinin in ischemic neurological complications after cardiac surgery Assessment of relation between neutrophil lympocyte, platelet lympocyte ratios and epicardial fat thickness in patients with ankylosing spondylitis See full issue

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.